Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Jul 12;11:6553–6566. doi: 10.2147/CMAR.S202342

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2019 Quan et al.

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).

PMC Copyright notice

Ezrin promotes proliferation and invasion of pancreatic cancer cells through activating Akt/mTOR pathway.

Notes: (A) The expression of Akt, p-Akt, mTOR, and p-mTOR was detected in Ezrin knockdown and overexpression cells by Western blot. β-Actin was set as the loading control. (B) The expression of Akt, mTOR, E-cadherin, and Vimentin was detected in Ezrin-overexpressed BxPC-3 cells after treatment with rapamycin or LY294002 by Western blot. β-Actin was set as the loading control. (C) Colony formation capacity was detected in Ezrin-overexpressed BxPC-3 cells after treatment with rapamycin or LY294002. (D) Invasion capacity was detected in Ezrin-overexpressed BxPC-3 cells after treatment with rapamycin or LY294002. *P<0.05, **P<0.01.